Replaces Prod. #: BML-CA215
Blocks slow voltage-sensitive L-type Ca2+ channels. Adrenergic antagonist. Inhibits platelet-activating factor and PMA-stimulated prostaglandin production in Kupffer cells. Induces apoptosis. In vitro resistance modifier in drug resistant human tumor cell lines.
Product Details
Alternative Name: | 5-[(3,4-Dimethoxyphenylethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropyl-valeronitrile . HCl |
|
Formula: | C27H38N2O4 . HCl |
|
MW: | 454.6 . 36.5 |
|
CAS: | 152-11-4 |
|
MI: | 14: 9950 |
|
RTECS: | YV8320000 |
|
Purity: | ≥99% (HPLC) |
|
Identity: | Determined by IR. |
|
Appearance: | White crystalline powder. |
|
Solubility: | Soluble in 100% ethanol (26mg/ml), methanol or water (83mg/ml). |
|
Shipping: | Ambient |
|
Long Term Storage: | Ambient |
|
Regulatory Status: | RUO - Research Use Only |
|
Please mouse over
Product Literature References
In vitro assessment of the inhibitory effect of goreisan extract and its ingredients on the P-glycoprotein drug transporter and cytochrome P-450 metabolic enzymes: M. Takiyama, et al.; Xenobiotica
52, 511 (2022),
Abstract;
Pharmacokinetic study of Ninjin'yoeito: Absorption and brain distribution of Ninjin'yoeito ingredients in mice: T. Matsumoto, et al.; J. Ethnopharmacol.
279, 114332 (2021),
Abstract;
Targeting KRAS4A splicing through the RBM39/DCAF15 pathway inhibits cancer stem cells: W. C. Chen, et al.; Nat. Commun.
12, 4288 (2021),
Abstract;
Short-term exposure to L-type calcium channel blocker, verapamil, alters the expression pattern of calcium-binding proteins in the brain of goldfish, Carassius auratus: N.V. Palande, et al.; Comp. Biochem. Physiol. C: Tocicol. Pharmacol.
176-177, 31 (2015),
Application(s): Cell culture in fish,
Abstract;
Apoptosis induced by hyperthermia and verapamil in vitro in a human colon cancer cell line: I.B. Shchepotin, et al.; Int. J. Hyperthermia
13, 547 (1997),
Abstract;
Hyperthermia and verapamil inhibit the growth of human colon cancer xenografts in vivo through apoptosis: I.B. Shchepotin, et al.; Anticancer Res.
17, 2213 (1997),
Abstract;
Neuron degeneration induced by verapamil and attenuated by EGb761: L. Zhu, et al.; J. Basic Clin. Physiol. Pharmacol.
8, 301 (1997),
Abstract;
Apoptosis of human primary and metastatic colon adenocarcinoma cell lines in vitro induced by 5-fluorouracil, verapamil, and hyperthermia: I.B. Shchepotin, et al.; Anticancer Res.
14, 1027 (1994),
Abstract;
Effect of high-dose verapamil administration on the Ca2+ channel density in rat cardiac tissue: B.B. Lonsberry, et al.; Pharmacology
49, 23 (1994),
Abstract;
Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex: D. Piwnica-Worms, et al.; Cancer Res.
53, 977 (1993),
Abstract;
Goodman and Gilman's The Pharmacological Basis of Therapeutics, vol. 8; p. 774 (1990),
Drug action and cellular calcium regulation: R. Janis, et al.; Adv. Drug Res. 16, 309 (1987),
Calcium antagonism and calcium entry blockade: T. Godfraind, et al.; Pharmacol. Rev.
38, 321 (1986),
Abstract;
Participation of intracellular sites in the action of Ca2+ channel blockers: E.J. White & H.F. Bradford; Eur. J. Pharmacol.
130, 243 (1986),
Abstract;
The interaction of phenylalkylamine calcium channel blockers with the 1,4-dihydropyridine binding site: R.H. Zobrist, et al.; J. Mol. Cell. Cardiol.
18, 963 (1986),
Abstract;
Effect of trifluoperazine, compound 48/80, TMB-8 and verapamil on the rate of calmodulin binding to erythrocyte Ca2+-ATPase: O. Scharff & B. Foder; Biochim. Biophys. Acta
772, 29 (1984),
Abstract;
alpha-adrenergic antagonists as possible calcium channel inhibitors: D. Atlas & M. Adler; PNAS
78, 1237 (1981),
Abstract;
Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle: A. Fleckenstein; Ann. Rev. Pharmacol.
17, 149 (1977),
Abstract;